Roivant Sciences (ROIV) Stock Forecast, Price Target & Predictions
ROIV Stock Forecast
Roivant Sciences stock forecast is as follows: an average price target of $16.21 (represents a 40.59% upside from ROIV’s last price of $11.53) and a rating consensus of 'Buy', based on 10 wall street analysts offering a 1-year stock forecast.
ROIV Price Target
The average price target for Roivant Sciences (ROIV) is $16.21 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $20.00 to $12.50. This represents a potential 40.59% upside from ROIV's last price of $11.53.
ROIV Analyst Ratings
According to 10 Wall Street analysts, Roivant Sciences's rating consensus is 'Buy'. The analyst rating breakdown for ROIV stock is 0 'Strong Buy' (0.00%), 9 'Buy' (90.00%), 1 'Hold' (10.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Roivant Sciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 21, 2024 | David Risinger | Leerink Partners | $17.00 | $11.92 | 42.62% | 47.44% |
| Sep 19, 2024 | Corinne Jenkins | Goldman Sachs | $17.00 | $12.05 | 41.02% | 47.44% |
| Sep 11, 2024 | Chi Fong | Bank of America Securities | $12.50 | $12.46 | 0.36% | 8.41% |
| May 31, 2024 | Allison Bratzel | Piper Sandler | $20.00 | $10.39 | 92.49% | 73.46% |
| Apr 03, 2024 | Douglas Tsao | H.C. Wainwright | $18.00 | $10.92 | 64.84% | 56.11% |
| Apr 03, 2024 | Neena Bitritto-Garg | Deutsche Bank | $15.00 | $10.92 | 37.36% | 30.10% |
| Apr 02, 2024 | Corinne Jenkins | Goldman Sachs | $18.00 | $10.92 | 64.84% | 56.11% |
| Mar 13, 2024 | Corinne Jenkins | Goldman Sachs | $16.00 | $10.62 | 50.66% | 38.77% |
| Jan 05, 2023 | - | Citigroup | $14.00 | $7.56 | 85.19% | 21.42% |
| Dec 19, 2022 | - | Leerink Partners | $10.00 | $7.32 | 36.61% | -13.27% |
The latest Roivant Sciences stock forecast, released on Oct 21, 2024 by David Risinger from Leerink Partners, set a price target of $17.00, which represents a 42.62% increase from the stock price at the time of the forecast ($11.92), and a 47.44% increase from ROIV last price ($11.53).
Roivant Sciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 3 | 8 |
| Avg Price Target | $17.00 | $15.50 | $16.69 |
| Last Closing Price | $11.53 | $11.53 | $11.53 |
| Upside/Downside | 47.44% | 34.43% | 44.75% |
In the current month, the average price target of Roivant Sciences stock is $17.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 47.44% increase as opposed to Roivant Sciences's last price of $11.53. This month's average price target is up 9.68% compared to last quarter, and up 1.86% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 21, 2024 | Leerink Partners | Outperform | Outperform | Hold |
| Sep 19, 2024 | Goldman Sachs | Buy | Buy | Hold |
| Sep 11, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Sep 11, 2024 | Piper Sandler | Buy | Buy | Hold |
| Sep 11, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Sep 11, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 11, 2024 | Bank of America Securities | Neutral | Neutral | Hold |
| Jul 10, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| May 31, 2024 | Goldman Sachs | Underperform | Underperform | Hold |
| May 31, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Roivant Sciences's last stock rating was published by Leerink Partners on Oct 21, 2024. The company gave ROIV a "Outperform" rating, the same as its previous rate.
Roivant Sciences Financial Forecast
Roivant Sciences Revenue Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $37.14M | $18.42M | - | $27.38M | $17.05M | $12.53M | $4.32M | $9.22M | $24.34M | $13.99M |
| Avg Forecast | $40.00M | $38.00M | $36.00M | $34.00M | $86.23M | $79.18M | $66.57M | $53.08M | $45.04M | $32.06M | $48.63M | $30.72M | $31.01M | $31.77M | $27.11M | $24.49M | $18.17M | $14.78M | $5.70M | $7.18M | $13.35M | $9.87M | $7.22M |
| High Forecast | $40.00M | $38.00M | $36.00M | $34.00M | $86.23M | $79.18M | $66.57M | $53.08M | $45.04M | $32.06M | $78.22M | $30.72M | $31.05M | $38.53M | $47.69M | $24.49M | $18.17M | $14.78M | $5.70M | $7.18M | $13.35M | $9.87M | $7.22M |
| Low Forecast | $40.00M | $38.00M | $36.00M | $34.00M | $86.23M | $79.18M | $66.57M | $53.08M | $45.04M | $32.06M | $36.58M | $30.72M | $30.96M | $25.41M | $21.06M | $24.49M | $18.17M | $14.78M | $5.70M | $7.18M | $13.35M | $9.87M | $7.22M |
| # Analysts | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 9 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.17% | 0.68% | - | 1.51% | 1.15% | 2.20% | 0.60% | 0.69% | 2.47% | 1.94% |
Roivant Sciences's average Quarter revenue forecast for Mar 24 based on 3 analysts is $31.01M, with a low forecast of $30.96M, and a high forecast of $31.05M. ROIV's average Quarter revenue forecast represents a -16.51% decrease compared to the company's last Quarter revenue of $37.14M (Dec 23).
Roivant Sciences EBITDA Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 9 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-224.78M | $-276.45M | - | $-203.10M | $-221.04M | $-267.50M | $-322.63M | $-195.90M | $-207.99M | $-1.16B |
| Avg Forecast | $-24.00M | $-22.80M | $-21.60M | $-20.40M | $-51.74M | $-47.51M | $-39.94M | $-31.85M | $-27.03M | $-19.23M | $-29.18M | $-18.43M | $-18.60M | $-19.06M | $-16.26M | $-14.69M | $-10.90M | $-8.87M | $-3.42M | $-4.31M | $-8.01M | $-268.61M | $-4.33M |
| High Forecast | $-24.00M | $-22.80M | $-21.60M | $-20.40M | $-51.74M | $-47.51M | $-39.94M | $-31.85M | $-27.03M | $-19.23M | $-21.95M | $-18.43M | $-18.58M | $-15.24M | $-12.63M | $-14.69M | $-10.90M | $-8.87M | $-3.42M | $-4.31M | $-8.01M | $-214.89M | $-4.33M |
| Low Forecast | $-24.00M | $-22.80M | $-21.60M | $-20.40M | $-51.74M | $-47.51M | $-39.94M | $-31.85M | $-27.03M | $-19.23M | $-46.93M | $-18.43M | $-18.63M | $-23.12M | $-28.62M | $-14.69M | $-10.90M | $-8.87M | $-3.42M | $-4.31M | $-8.01M | $-322.33M | $-4.33M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.79% | 17.00% | - | 18.63% | 24.93% | 78.21% | 74.91% | 24.46% | 0.77% | 267.79% |
undefined analysts predict ROIV's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Roivant Sciences's previous annual EBITDA (undefined) of $NaN.
Roivant Sciences Net Income Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 9 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $5.10B | $-304.33M | - | $-175.42M | $-384.90M | $-315.92M | $-353.78M | $-291.31M | $-306.08M | $-225.64M |
| Avg Forecast | $-250.12M | $-242.30M | $-234.49M | $-226.67M | $-207.13M | $-224.72M | $-226.67M | $-215.73M | $-203.22M | $-221.98M | $-182.12M | $-190.19M | $-206.62M | $-241.52M | $-225.11M | $-221.46M | $-282.45M | $-308.34M | $-296.07M | $-249.79M | $-239.10M | $-268.64M | $-254.11M |
| High Forecast | $-250.12M | $-242.30M | $-234.49M | $-226.67M | $-207.13M | $-224.72M | $-226.67M | $-215.73M | $-203.22M | $-221.98M | $-147.43M | $-190.19M | $-206.62M | $-187.85M | $-167.02M | $-221.46M | $-282.45M | $-308.34M | $-296.07M | $-249.79M | $-239.10M | $-214.91M | $-254.11M |
| Low Forecast | $-250.12M | $-242.30M | $-234.49M | $-226.67M | $-207.13M | $-224.72M | $-226.67M | $-215.73M | $-203.22M | $-221.98M | $-234.15M | $-190.19M | $-206.62M | $-268.36M | $-246.89M | $-221.46M | $-282.45M | $-308.34M | $-296.07M | $-249.79M | $-239.10M | $-322.37M | $-254.11M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -21.10% | 1.35% | - | 0.62% | 1.25% | 1.07% | 1.42% | 1.22% | 1.14% | 0.89% |
Roivant Sciences's average Quarter net income forecast for Mar 24 is $-206.62M, with a range of $-206.62M to $-206.62M. ROIV's average Quarter net income forecast represents a -104.05% decrease compared to the company's last Quarter net income of $5.10B (Dec 23).
Roivant Sciences SG&A Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 9 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $197.28M | $164.35M | - | $125.51M | $168.26M | $157.66M | $149.07M | $138.97M | $115.53M | $437.78M |
| Avg Forecast | $361.67M | $343.58M | $325.50M | $307.42M | $779.63M | $715.88M | $601.95M | $479.96M | $407.27M | $289.84M | $439.74M | $277.75M | $280.36M | $287.29M | $245.08M | $221.40M | $164.27M | $133.61M | $51.54M | $64.90M | $120.69M | $89.21M | $65.30M |
| High Forecast | $361.67M | $343.58M | $325.50M | $307.42M | $779.63M | $715.88M | $601.95M | $479.96M | $407.27M | $289.84M | $707.24M | $277.76M | $280.77M | $348.36M | $431.24M | $221.40M | $164.27M | $133.61M | $51.54M | $64.90M | $120.69M | $89.21M | $65.30M |
| Low Forecast | $361.67M | $343.58M | $325.50M | $307.42M | $779.63M | $715.88M | $601.95M | $479.96M | $407.27M | $289.84M | $330.72M | $277.75M | $279.96M | $229.72M | $190.40M | $221.40M | $164.27M | $133.61M | $51.54M | $64.90M | $120.69M | $89.21M | $65.30M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.69% | 0.67% | - | 0.76% | 1.26% | 3.06% | 2.30% | 1.15% | 1.30% | 6.70% |
Roivant Sciences's average Quarter SG&A projection for Mar 24 is $280.36M, based on 3 Wall Street analysts, with a range of $279.96M to $280.77M. The forecast indicates a 42.11% rise compared to ROIV last annual SG&A of $197.28M (Dec 23).
Roivant Sciences EPS Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 9 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $6.37 | $-0.40 | - | $-0.24 | $-0.54 | $-0.45 | $-0.51 | $-0.42 | $-0.45 | $-0.33 |
| Avg Forecast | $-0.32 | $-0.31 | $-0.30 | $-0.29 | $-0.27 | $-0.29 | $-0.29 | $-0.28 | $-0.26 | $-0.28 | $-0.23 | $-0.24 | $-0.26 | $-0.31 | $-0.29 | $-0.28 | $-0.36 | $-0.39 | $-0.38 | $-0.32 | $-0.31 | $-0.25 | $-0.33 |
| High Forecast | $-0.32 | $-0.31 | $-0.30 | $-0.29 | $-0.27 | $-0.29 | $-0.29 | $-0.28 | $-0.26 | $-0.28 | $-0.19 | $-0.24 | $-0.26 | $-0.24 | $-0.21 | $-0.28 | $-0.36 | $-0.39 | $-0.38 | $-0.32 | $-0.31 | $-0.25 | $-0.33 |
| Low Forecast | $-0.32 | $-0.31 | $-0.30 | $-0.29 | $-0.27 | $-0.29 | $-0.29 | $-0.28 | $-0.26 | $-0.28 | $-0.30 | $-0.24 | $-0.26 | $-0.34 | $-0.32 | $-0.28 | $-0.36 | $-0.39 | $-0.38 | $-0.32 | $-0.31 | $-0.25 | $-0.33 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -20.61% | 1.39% | - | 0.66% | 1.37% | 1.19% | 1.60% | 1.37% | 1.77% | 1.02% |
According to 3 Wall Street analysts, Roivant Sciences's projected average Quarter EPS for Mar 24 is $-0.26, with a low estimate of $-0.26 and a high estimate of $-0.26. This represents a -104.15% decrease compared to ROIV previous annual EPS of $6.37 (Dec 23).
Roivant Sciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| INZY | Inozyme Pharma | $4.42 | $14.67 | 231.90% | Buy |
| PLRX | Pliant Therapeutics | $14.49 | $39.71 | 174.05% | Buy |
| APLS | Apellis Pharmaceuticals | $28.56 | $76.13 | 166.56% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.81 | $38.80 | 161.99% | Buy |
| CGEM | Cullinan Oncology | $15.92 | $31.50 | 97.86% | Buy |
| LYRA | Lyra Therapeutics | $0.26 | $0.50 | 92.31% | Hold |
| SNDX | Syndax Pharmaceuticals | $18.94 | $36.11 | 90.65% | Buy |
| VRDN | Viridian Therapeutics | $22.84 | $37.83 | 65.63% | Buy |
| ASND | Ascendis Pharma | $125.77 | $190.21 | 51.24% | Buy |
| AKRO | Akero Therapeutics | $32.05 | $46.00 | 43.53% | Buy |
| ROIV | Roivant Sciences | $11.53 | $16.21 | 40.59% | Buy |
| PHAT | Phathom Pharmaceuticals | $18.94 | $25.83 | 36.38% | Buy |
| BGNE | BeiGene | $207.25 | $255.80 | 23.43% | Buy |
| BPMC | Blueprint Medicines | $91.88 | $109.71 | 19.41% | Buy |
| KRYS | Krystal Biotech | $170.85 | $191.00 | 11.79% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $55.87 | $58.57 | 4.83% | Buy |
| RXDX | Prometheus Biosciences | $199.92 | $138.57 | -30.69% | Buy |
ROIV Forecast FAQ
Is Roivant Sciences a good buy?
Yes, according to 10 Wall Street analysts, Roivant Sciences (ROIV) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 9 'Buy' recommendations, accounting for 90.00% of ROIV's total ratings.
What is ROIV's price target?
Roivant Sciences (ROIV) average price target is $16.21 with a range of $12.5 to $20, implying a 40.59% from its last price of $11.53. The data is based on 10 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Roivant Sciences stock go up soon?
According to Wall Street analysts' prediction for ROIV stock, the company can go up by 40.59% (from the last price of $11.53 to the average price target of $16.21), up by 73.46% based on the highest stock price target, and up by 8.41% based on the lowest stock price target.
Can Roivant Sciences stock reach $20?
ROIV's average twelve months analyst stock price target of $16.21 does not support the claim that Roivant Sciences can reach $20 in the near future.
What is Roivant Sciences's current price target trend?
1 Wall Street analyst forecast a $17 price target for Roivant Sciences (ROIV) this month, up 47.44% from its last price of $11.53. Compared to the last 3 and 12 months, the average price target increased by 34.43% and increased by 44.75%, respectively.
What are Roivant Sciences's analysts' financial forecasts?
Roivant Sciences's analysts financial forecasts for the fiscal year (Mar 2026) are as follows: average revenue is $285.06M (high $285.06M, low $285.06M), average EBITDA is $-171M (high $-171M, low $-171M), average net income is $-874M (high $-874M, low $-874M), average SG&A $2.58B (high $2.58B, low $2.58B), and average EPS is $-1.119 (high $-1.119, low $-1.119). ROIV's analysts financial forecasts for the fiscal year (Mar 2027) are as follows: average revenue is $148M (high $148M, low $148M), average EBITDA is $-88.8M (high $-88.8M, low $-88.8M), average net income is $-954M (high $-954M, low $-954M), average SG&A $1.34B (high $1.34B, low $1.34B), and average EPS is $-1.22 (high $-1.22, low $-1.22).
Did the ROIV's actual financial results beat the analysts' financial forecasts?
Based on Roivant Sciences's last annual report (Mar 2023), the company's revenue was $28.01M, which missed the average analysts forecast of $45.82M by -38.87%. Apple's EBITDA was $-1.175B, beating the average prediction of $-27.493M by 4174.89%. The company's net income was $-1.23B, beating the average estimation of $-1.137B by 8.21%. Apple's SG&A was $600.51M, beating the average forecast of $414.31M by 44.94%. Lastly, the company's EPS was $-1.73, beating the average prediction of $-1.454 by 18.96%. In terms of the last quarterly report (Dec 2023), Roivant Sciences's revenue was $37.14M, beating the average analysts' forecast of $31.77M by 16.89%. The company's EBITDA was $-225M, beating the average prediction of $-19.064M by 1079.06%. Roivant Sciences's net income was $5.1B, missing the average estimation of $-242M by -2210.02%. The company's SG&A was $197.28M, missing the average forecast of $287.29M by -31.33%. Lastly, the company's EPS was $6.37, missing the average prediction of $-0.309 by -2161.49%